Nyxoah SA (EBR:NYXH)

Market Cap	177.27M
Revenue (ttm)	5.64M
Net Income (ttm)	-83.72M
Shares Out	43.03M
EPS (ttm)	-2.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,800
Average Volume	55,751
Open	4.100
Previous Close	n/a
Day's Range	4.075 - 4.260
52-Week Range	3.840 - 11.150
Beta	0.65
RSI	45.84
Earnings Date	Mar 13, 2026

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 184
• Stock Exchange: Euronext Brussels
• Ticker Symbol: NYXH

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.